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Abstract
The role of tumor necrosis factor a (TNF) in neural function has been investigated extensively in several neurodegenerative
conditions, but rarely in brain aging, where cognitive and physiologic changes are milder and more variable. Here, we show
that protein levels for TNF receptor 1 (TNFR1) are significantly elevated in the hippocampus relative to TNF receptor 2
(TNFR2) in aged (22 months) but not young adult (6 months) Fischer 344 rats. To determine if altered TNF/TNFR1
interactions contribute to key brain aging biomarkers, aged rats received chronic (4–6 week) intracranial infusions of
XPro1595: a soluble dominant negative TNF that preferentially inhibits TNFR1 signaling. Aged rats treated with XPro1595
showed improved Morris Water Maze performance, reduced microglial activation, reduced susceptibility to hippocampal
long-term depression, increased protein levels for the GluR1 type glutamate receptor, and lower L-type voltage sensitive
Ca
2+ channel (VSCC) activity in hippocampal CA1 neurons. The results suggest that diverse functional changes associated
with brain aging may arise, in part, from selective alterations in TNF signaling.
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Introduction
The cytokine tumor necrosis factor-alpha (TNF) plays a critical
role in coordinating and maintaining immune/inflammatory
responses both inside and outside the brain. TNF binds to two
distinct membrane receptor subtypes, TNFR1 and TNFR2, which
are, in turn, coupled to distinct intracellular signaling cascades.
TNFR1 contains a classic ‘‘cytoplasmic cell death’’ domain and is
most commonly implicated in pathological processes, while
TNFR2 (which lacks the death domain) preferentially engages
pathways that promote cell survival [1]. Aging and several
neurodegenerative diseases are associated with elevated brain
levels of TNF [2,3,4,5,6]. In animal models of disease, TNF
appears to be a key contributor to chronic glial activation and
impaired neuronal viability through its actions on TNFR1 [7].
However, the role of TNF and its receptor mechanisms in aging
brain remain unclear.
In contrast to most disease models, aged animals exhibit
neurologic changes that are generally milder and more variable in
nature. These changes usually include synaptic dysfunction and
Ca
2+ dysregulation [8,9], both of which can be precipitated in
healthy young adult animals and/or in neuronal cultures in
response to artificial elevations in TNF [10,11,12]. Perhaps most
relevant to the aging neurologic phenotype is evidence from
neuronal culture studies showing that TNF potentiates the activity
of L-type voltage sensitive Ca
2+ channels (L-VSCCs) [11]. A
similar potentiation of L-VSCC activity has been well-character-
ized in hippocampal neurons of memory impaired aged rats [13]
and is a primary mechanism for alterations in short and long-
lasting forms of synaptic plasticity [9].
While a recent behavioral study in aged rats showed that TNF
blockade in the cerebellum accelerated learning in a delayed
eyeblink task [14], no studies that we know of have directly
investigated the impact of TNF on synaptic and Ca
2+ signaling
mechanisms during aging. Here, we report that protein levels for
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7the major TNFRs are altered in the hippocampus of aged Fischer
344 rats, in favor of TNFR1 signaling. Furthermore, selective
blockade of TNF/TNFR1 interactions in aged rats over a four-to-
six week period using a novel anti-TNF biologic (XPro1595)
improved behavioral performance on a Morris swim task, reduced
microglial activation, prevented the induction of hippocampal
long-term depression (LTD), and reduced the activity of L-VSCCs
in CA1 neurons. Together, the results suggest that TNF/TNFR1
interactions play an important role in shaping the neurologic
phenotype of aged animals and could set the stage for further
pathological changes associated with neurologic disease.
Methods
Ethics Statement
All animal procedures were compliant with the guidelines of the
UniversityofKentuckyinstitutionalAnimalUseCommitteeandthe
AmericanAssociationforAccreditationofLaboratoryAnimalCare.
Animals
Studies used six- or twenty-two-month-old Fischer 344 rats
(National Institute on Aging) which were housed separately,
provided ad libitum food and water, and maintained on a 12 h:12 h
light:dark cycle.
Surgeries
Rats were anaesthetized with isoflurane (2.5%) and immobilized
in a stereotaxic frame. Depending on the study, cannulae were
inserted unilaterally into the right lateral ventricle (from Bregma
21, +1.4 mm lateral), or bilaterally into the hippocampus (from
Bregma, 23.8, 62 mm lateral). Cannulae were connected to
osmotic pumps (Alzet, Model 2004 or Model 2006 for four and
six week delivery periods, respectively) inserted subcutaneously
behind the shoulders. Rats that showed weight loss of more than
10 grams after surgery were provided a high-calorie food
supplement until their weight stabilized. If other problems were
discovered, which were rare and usually not related to surgery,
treatment recommendations from the veterinarian staff were
followed. Osmotic pumps were charged with either vehicle or
XPro1595 (0.08 mg/kg/day), a novel dominant-negative TNF
(formerly XENP1595 [15]) manufactured by Xencor. XPro1595
selectively inhibits soluble TNF (solTNF) signaling by exchanging
subunits with solTNF trimers for subunits with disrupted receptor
binding surfaces, therefore preventing interaction with TNF
receptors [16], but primarily inhibiting TNFR1 which has much
greater affinity for solTNF [17]. Transmembrane TNF (tmTNF)
function is spared by XPro1595 therapy, maintaining the
protective roles of TNF which occur primarily through TNFR2
signaling [15]. Though initially developed for targeting TNF
signaling in peripheral tissues, Xpro1595, or similar compounds
from Xencor, have been shown to inhibit TNF-mediated
activation of NFkB in a neural cell line [18] and prevent
microglial activation in primary murine cell cultures [18] and in
intact animal models of Parkinson’s disease [19], suggesting that
XPro1595 should effectively inhibit TNF signaling in the
hippocampus of aged rats.
Morris Water Maze
The water maze was a black circular pool (183 cm in diameter)
filled with water heated to 27uC. Each subject’s path in the pool
was recorded with Videomex Water Maze Monitoring Software
(Columbus Instruments, Columbus, OH) and analyzed off-line. All
animals were first screened for visual and/or motor impairments
using a visual cue version of the water maze [20]. Two days after
the cue task, rats received training on a spatial version of the
Morris Water Maze according to methods previously described by
our group [20,21]. The all-black escape platform, located about
1.5 cm below the water’s surface, remained in the same quadrant
across trials for each group of animals, but varied from group to
group. The curtains surrounding the pool were removed, revealing
extra-maze cues within the room, including high-contrast, black
and white poster boards. Starting locations were randomized
across trials. Training consisted of six blocks of three trials (60 s/
trial) with an inter-trial interval of 60 s and an inter-block interval
of 20–30 min. Latency and path length traveled to escape were
used to measure performance on each trial.
Synaptic strength and plasticity measures in intact
hippocampal slices
Methods for preparation of hippocampal slices are similar to that
described previously by our group [22]. Four to fourteen days after
behavioral assessment, rats were anesthetized deeply with CO2 and
then decapitated. Brains were removed rapidly and stored briefly in
Ca
2+-free chilled, oxygenated (95% O2/5% CO2) artificial
cerebrospinal fluid (aCSF) before hippocampi were dissected. The
composition of aCSF was (in mM): 124 NaCl, 2 KCl, 1.25 K2PO4,
2 MgSO4, 2 CaCl2, 26 NaHCO3, 10 dextrose, pH=7.4. Hippo-
campal slices (450 mm), cut parallel to the alvear fibers, were
prepared with a McIlwain tissue chopper and transferred to a four-
well humidified interface holding chamber containing heated (30–
32uC) and oxygenated aCSF with 2 mM CaCl.
After 1–1.5 hours, slices were transferred to a modified RC-22
recording chamber (Warner Instruments) and perfused continu-
ously (1–1.5 ml/min) with oxygenated aCSF heated to 32uC. A
bipolar platinum-iridium stimulating electrode, positioned in
stratum radiatum near the CA3 border, was used to deliver 100 msec
diphasic, constant-current pulses to CA3 Schaffer collaterals.
Stimulus intensity was controlled by a constant current stimulus
isolation unit (World Precision Instruments). Stimulus timing was
controlled by a Multiclamp 700B amplifier and pClamp software
(Molecular Devices). A glass micropipette (1–6 MV), pulled from
thin-wall tubing (Drummond Scientific Company, 100 ml cali-
brated pipets), filled with aCSF and containing a Ag/AgCl wire,
was positioned about 1 mm from the stimulating electrode in
stratum radiatum of CA1. Field excitatory postsynaptic potentials
(EPSPs) were amplified 100X, Bessel-filtered at 1 kHz, and
digitized at 10 kHz.
For each slice, stimulus pulses were delivered at nine different
intensity levels (range 30–500 mA) at a rate of 0.1 Hz to establish a
synaptic strength curve. Five field potentials at each stimulus level
were averaged, and measurements of fiber volley (FV) amplitude
(in mV) and EPSP slope (in mV/ms) were performed offline using
pClamp software (Molecular Devices). The relative number of
activated CA3 afferents in each slice was assessed by plotting
average FV amplitudes against stimulation intensity. Averaged
EPSP slope measures were then plotted against their correspond-
ing FV amplitudes to estimate the strength of available CA3-CA1
synaptic contacts. Fiber excitability and synaptic strength curves
for each hemisphere were fit with a sigmoidal equation of the
form: a/(1+exp(2(x2x0)/b)), where a equals the maximal
amplitude of the distribution, b equals the distribution slope, and
x0 equals the stimulation intensity (or FV amplitude) required for
half-maximal response amplitude. Fitted parameters were then
compared across treatment groups using Z tests. Z values greater
than |2| were considered significant. After the synaptic strength
curve, stimulation intensity for each slice was readjusted to elicit an
EPSP of ,1 mV. Stimulus pulses were then delivered at 0.033 Hz
until a stable 20 min baseline was established. Low-frequency
Tumor Necrosis Factor Signaling and Brain Aging
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term depression (LTD), followed by an additional 60 min baseline.
For each animal, electrophysiological parameters were averaged
across all slices (usually one to three slices) and the n used for all
statistical comparisons reflects the number of animals per drug
treatment group. Within each treatment group, EPSP slope
measurements from the last 10 min of the post-LTD baseline were
averaged across slices and compared to the pre-LTD baseline
slope average. Differences across groups were determined by
repeated measures ANOVA, with significance at p,0.05.
L-VSCC activity measurements in hippocampal zipper
slices
Acute hippocampal slices were prepared from rats as described
above and then partially dissociated along the CA1 cell body layer
to create ‘‘zipper’’ slices as described previously [13,23,24,25,26].
Immediately before electrophysiologic recordings, each slice was
nicked with a scalpel blade at the CA1 cell body layer and
transferred to a small microcentrifuge tube containing approxi-
mately 1 ml of Ca
2+-free aCSF with 10 mM EGTA. Slices were
then shaken gently by hand and monitored periodically for
dissociation along CA1 stratum pyramidale before transfer to a
perfusion-style recording chamber (Warner Instruments) contain-
ing recording medium. A 40x objective was used to identify cleanly
exposed CA1 pyramidal neurons, suitable for recording. On-cell
patch extracellular recording solution contained (in mM): 140 K
gluconate, 3 MgCl2, 10 glucose, 10 EGTA, and 10 HEPES,
pH 7.35, osmolarity =300 mOsm. On-cell patch pipette solution
consisted of (in mM): 20 BaCl2, 90 choline Cl, 10 TEA Cl, and 10
HEPES, pH 7.35, osmolarity =290 mOsm.
On-cell recording patch pipettes consisted of fire-polished,
Sylgard-coated, glass capillary tubes with tip resistances averaging
5.8960.07 MV across groups. All recordings were obtained at
room temperature using an Axopatch 200A patch-clamp amplifier
and pClamp software (Molecular Devices). Seal quality was
determined using the seal test feature of pClamp. Patches that
sealed slowly (.30 sec) or showed a seal resistance ,10 GV were
excluded from statistical analysis. A total of 25 patches for vehicle-
treated rats and 28 patches for XPro1595-treated rats were used
for statistical analysis. Maximal current in each patch was
achieved by stepping the patch membrane from its holding
potential of 270 to +10 mV. A series of 45250 steps to +10 mV
(15 s inter-step interval) was used to generate an average ensemble
current for each patch. Currents were leak-subtracted off-line
using hyperpolarizing pulses, identical in duration and opposite in
polarity. Current density (pA/mm
2) for each patch was derived by
dividing the average ensemble current by the patch area. Patch
area, which is inversely proportional to the pipette resistance, was
estimated for each recording using the equation a=12.6(1/R +
0.018), where ‘a’ is the patch area and ‘R’ is the pipette resistance
[27]. Data were filtered at 2 kHz and digitized at 5 kHz.
Measurement of hippocampal proteins
For each rat, one hippocampus was flash-frozen in liquid
nitrogen and stored at 280uC for later use. Cytosolic and nuclear
fractions from hippocampal samples were prepared with modifi-
cations of the protocol used by Ohlsson and Edlund [28]. Briefly,
the thawed hippocampus was homogenized in buffer A [25 mM
HEPES, pH 7.0, 25 mM KCl, 5 mM MgCl2, 0.05 mM EDTA,
10% glycerol, 0.1% NP-40, and 1 mM dithiothreitol (DTT),
phosphatase inhibitor, protease inhibitor, calpain inhibitors] and
centrifuged for 15 min at 3000 rpm (4uC). The resulting pellet was
resuspended in Buffer C [50 mM HEPES, pH 7.6, 50 mM KCl,
0.1 mM EDTA, 10% glycerol, 1 mM dithiothreitol, phosphatase
inhibitor, protease inhibitor, calpain inhibitors, and 0.3 M
ammonium sulfate], incubated on a rocking platform for 30 min
(4uC) and then ultracentrifuged at 37,000 rpm for 15 min at 4uC
to remove nuclear debris. Proteins in the supernatant were
precipitated by adding an equal volume of 3 M ammonium
sulfate, incubated on a rocking platform for 15 min at 4uC, and
ultracentrifuged at 37,000 rpm for 15 min. The pellet obtained,
which contained the nuclear fraction, was resuspended in 150 ml
of buffer C and stored at –80uC. The supernatant collected from
the initial 3000 rpm centrifugation step described above was
processed through a series of three 15 min ultracentrifugation
(37,000 rpm) steps. After the first spin, the pellet obtained
contained the membrane fraction and was resuspended in
200 ml of 0.3 M sucrose buffer and stored at –80uC until use.
Then, buffer B [0.3 M HEPES, pH 7.6, 50 mM KCl, 0.1 mM
EDTA, 1 mM DTT, phosphatase inhibitor, protease inhibitor,
calpain inhibitors] was added to the supernatant at 1/10
th the
volume and spun a second time. The resulting supernatant was
combined with 0.3 g/ml ammonium sulfate, rotated for 30 min at
4uC for protein precipitation, and then spun a third time. The
resulting pellet, which contained the cytosolic fraction, was
resuspended in 200 ml of buffer C and stored at –80uC until use.
Protein levels of the membrane and cytosolic fractions were
estimated using the Lowry method. Samples were loaded into
individual lanes of Bio-Rad pre-cast gels (7.5% or 4–20%
gradient), or into freshly cast 10% SDS-PAGE gels with protein
concentrations held constant across lanes. Proteins were resolved
by electrophoresis and transferred to polyvinylidene difluoride
membranes for semi-quantitative Western blot. Membranes were
incubated at 4uC overnight in 5% non-fat milk along with primary
antibodies, which included mouse anti-NR1 1:2000 (Millipore),
rabbit anti-NR2A 1:3000 (Millipore), rabbit anti-NR2B 1:2000
(Millipore), rabbit anti-GluR1 1:2000 (Millipore), anti-GluR2
1:1000 (Santa Cruz Biotechnology), rabbit anti-CaV1.2 1:2000
(Alamone Labs), rabbit anti-CaV1.3 1:1000 (Alamone Labs),
mouse anti-GFAP 1:10,000 (Cell Signaling Technology), goat
Figure 1. Increased TNFR1/TNFR2 ratio during aging. A,
Representative Western blots for TNFR1 and TNFR2 in hippocampal
membrane fractions from young (6 mos; n=6) and aged (22 mos;
n=10) male Fischer rats, with the Na/K-ATPase loading control shown
below. B, There was no significant change in TNFR1 protein levels with
age (p=0.67); however, there was a significant decrease in TNFR2 with
age (* p,0.05).
doi:10.1371/journal.pone.0038170.g001
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1:250 (Santa Cruz Biotechnology), mouse anti-NaKATPase
1:10,000 (Abcam), and mouse anti-GAPDH 1:10,000 (Abcam).
Primary antibodies were tagged with an appropriate horseradish
peroxidase-conjugated secondary antibody, diluted in 5% non-fat
milk at 1:10,000, and detected using the ECL-plus Western kit
(GE Healthcare). Protein levels were quantified using a Storm 860
molecular imager.
Immunohistochemistry
Some hippocampal slices processed for electrophysiologic
recordings were subsequently used for immunohistochemical
labeling of microglia (with Iba-1) and astrocytes (with GFAP).
Slices were fixed in 4% paraformaldehyde overnight, preserved in
sucrose buffer, and further cut to 50 mM thickness using a freezing
microtome. Sections were mounted on gelatin-coated slides and
baked in an oven at 37uC for one week. Slices were rehydrated
through a series of ethanol washes to water before heat-induced
antigen retrieval (Diva Decloaking solution from Biocare Medical)
was performed.
For Iba-1 labeling, slide-mounted sections were first blocked for
1 hr at room temperature with phosphate buffer saline (PBS)
containing 10% donkey serum and then incubated overnight at
4uC with primary antibody, 1:500 rabbit anti-Iba-1 (Wako) in
PBS. Slides were washed three times with PBS and incubated for
2 h at room temperature with the secondary antibody, Alexa Fluor
594 1:500 donkey anti-rabbit (Jackson Immunoresearch Labora-
tories, Inc) diluted in blocking buffer. After rinsing three times with
PBS, sections were dehydrated, via a series of ethanol washes,
rinsed in 100% xylene and coverslipped with Prolong gold anti-
fading mounting reagent (Invitrogen). Cell fluorescence was
imaged with an inverted epifluorescence confocal microscope
(DMIRE-2, Leica).
For GFAP labeling, slide-mounted sections were first blocked
for 1 h at room temperature with Tris buffered saline (TBS)
containing 15% horse serum and then incubated overnight at 4uC
with primary antibody, 1:50 mouse monoclonal anti-GFAP (Cell
Signaling Technology Inc) in TBS. Slides were washed three times
with TBS and incubated for 2 h at room temperature with the
secondary antibody, 1:200 biotinylated horse anti-mouse (Vector
Laboratories, Inc) diluted in TBS. Sections were rinsed three times
with TBS and then incubated in ABC reagent (Vectastain ABC
Standard Kit, Vector Laboratories, Inc) for 1 h before being
developed with Nova Red, and then finally dehydrated, washed in
100% xylene, and coverslipped with mounting medium (Richard-
Allen Scientific). Sections were imaged with a Nikon Eclipse E800.
Figure 2. XPro1595 alters Iba-1 levels. XPro1595 (0.08 mg/kg/day) was administered to the hippocampus over a six week period using Alzet
osmotic pumps. Immunolabeling revealed a reduction in inflammatory phenotype in microglia (A, Iba-1) and, to a lesser extent, in astrocytes (D,
GFAP) of XPro1595 treated aged rats. CA1=CA1 stratum pyramidale. Representative Western blots and mean 6 SEM protein levels are for Iba-1 (B
and C) and GFAP (E and F) in hippocampal fractions of vehicle and XPro1595-treated rats. b-actin and GAPDH served as loading controls for Iba-1 and
GFAP, respectively. Results revealed a marked, significant reduction in Iba-1 protein levels (* p,0.05) and a smaller, nonsignificant reduction in GFAP
levels in the XPro1595 group (p=0.45).
doi:10.1371/journal.pone.0038170.g002
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Student’s t-test, with significance set at p,0.05, was used to
analyze Western blot protein levels, and cell-attached patch
‘‘zipper’’ L-VSCC current density. Repeated-measures analysis of
variance (rm-ANOVA), with significance set at p,0.05, was used
to analyze spatial learning in the Morris Water Maze, and the
extent of synaptic depression following the delivery of 1 Hz
stimulation. Z-test, with significance set at p,0.05, was used to
analyze the 3-parameter sigmoidal functions that were fit to the
fiber excitability and synaptic strength curves.
Results
Increased TNFR1/TNFR2 ratio during aging
TNF levels increase in the hippocampus during aging [2,3,4],
but little is known about the relative expression levels of TNFRs,
which play fundamental roles in determining the physiologic
outcome of elevated TNF [29]. To investigate TNFR levels,
hippocampal membrane fractions were prepared from six young
(6 month) and ten aged (22 month) male rats for Western blot
analysis of TNFR1 and TNFR2 (Figure 1A and 1B). The results
revealed a dramatic and significant drop (,70%) in membrane
TNFR2 levels in aged rats (p,0.05), while TNFR1 levels were
relatively unaffected by age (p=0.67). Accordingly, the ratio of
TNFR1 to total TNFR exhibited a significant increase in the aged
group suggesting that overall TNFR availability in aged rat
hippocampus favors TNFR1 signaling.
XPro1595 reduces signs of microglial activation in aged
rats
To determine the extent to which TNF/TNFR1 signaling
contributes to key brain aging biomarkers, we next treated aged
rats with the novel biologic XPro1595, manufactured by Xencor.
XPro1595 specifically targets and inactivates soluble TNF
(solTNF) trimers, but does not disrupt the function of transmem-
brane TNF (tmTNF) [15,16]. As TNFR1 exhibits high affinity to
solTNF, whereas TNFR2 shows greater affinity for tmTNF
[17,30], XPro1595 essentially acts as a selective inhibitor of
TNFR1 signaling [1,15,16]. XPro1595 was infused bilaterally into
the hippocampus of aged rats for six weeks using Alzet osmotic
pumps. Drug concentration and delivery rate (0.08 mg/kg/day)
was based on published work showing efficacy of a similar Xencor
construct in an intact rat model of Parkinson’s disease [19] and our
pilot studies.
In models of Parkinson’s disease, XPro1595 (or similar
constructs) strongly suppressed signs of neuroinflammation,
including the activation of microglia [19]. To determine the
extent to which TNF/TNFR1 signaling drives neuroinflammation
during normal aging, we labeled hippocampal sections prepared
from vehicle- and XPro1595-treated (n=10, n=10, respectively)
rats for the presence of Iba-1 (marker for microglial activation) or
GFAP (marker for astrocyte activation). Western blots were also
used to quantitatively assess levels of these proteins in hippocampal
homogenates. As shown in Figure 2A, Iba-1-labeled microglia
appeared less ramified in the hippocampus of XPro1595-treated
rats. Consistent with this observation, XPro1595 treatment was
associated with a significant reduction (p,0.05) in hippocampal
Iba1-protein levels as determined by Western Blot (Figure 2B, 2C).
A similar trend was observed for GFAP (Figure 2D–2F), though
differences between vehicle- and XPro1595-treated rats in
Western analyses did not reach statistical significance (p=0.45).
Thus, similar to that shown in Parkinson’s disease models,
XPro1595 also appears to exert anti-neuroinflammatory actions
during aging.
XPro1595 accelerates behavioral acquisition, reduces
age-related susceptibility to long-term depression, and
increases expression of GluR1 protein
Elevated levels of pro-inflammatory cytokines, including TNF,
have been suggested to negatively impact cognition and synaptic
plasticity in aging and age-related neurodegenerative disease
[6,10,31,32,33]. To investigate the extent to which TNF blockade
via hippocampal XPro1595 infusion (0.08 mg/kg/day) influences
cognitive status during aging, drug- and vehicle-treated (n=11,
n=13, respectively) rats were trained on the spatial version of the
Morris Water Maze. As shown in Figure 3A, both groups of
animals learned the task by block six (p,0.01). However, rats
treated for six weeks with XPro1595 exhibited significantly faster
acquisition rates (p,0.05) than the vehicle treated group,
suggesting that blockade of solTNF signaling improves learning
during aging.
Behavioral deficits in aged rats are associated with changes in
synaptic strength [34] and susceptibility to induction of long-term
depression (LTD) [35]. To determine if TNF/TNFR1 signaling
modulates synaptic strength parameters and LTD, XPro1595
(n=10) or vehicle (n=8) was delivered intraventricularly to aged
rats continuously (0.08 mg/kg/day) across a four week period
using micro-osmotic pumps. Field potentials in CA1 stratum
radiatum of CA1 were recorded in response to electrical stimulation
of CA3 Schaffer collaterals as described previously [36,37]. For
each slice, an input/output curve was constructed from nine
stimulus intensity levels. Fiber excitability (i.e. FV amplitude vs.
stimulus intensity, not shown) and synaptic strength (i.e. EPSP
slope amplitude vs FV amplitude, Figure 3B) data were fitted with
a three-parameter sigmoidal function and compared across groups
as described [38]. Results indicated no difference in slope or half-
maximal amplitude in the synaptic strength curve, but XPro1595-
treated rats did show a slight increase in the maximal EPSP
amplitude (Figure 3B; z=2.17), in the absence of a significant
effect on FV amplitude (not shown). In addition to synaptic
strength, measures of paired pulse-facilitation (PPF) were also
relatively insensitive to XPro1595 (Figure 3C), suggesting that
TNF signaling does not appreciably alter excitation-neurotrans-
mitter release coupling in aged rats.
LTD was induced in CA1 using low frequency stimulation
(1 Hz, 900 pulses) and data were analyzed using two-way repeated
measures ANOVA (Figure 3D and 3E). EPSP slope magnitudes
measured 60 min after 1 Hz trains were significantly reduced
relative to baseline in the vehicle treated aged group (p,0.05),
similar to previous findings [35,36,39,40]. Alternatively, slices
from XPro1595 treated animals showed nearly no depression
(about 3%) 60 min after 1 Hz stimulation, suggesting that TNF/
TNFR1 signaling is permissive for LTD induction during aging.
In addition to functional synaptic measures, we also used
Western blot to assess glutamate receptor protein levels in
membrane fractions from vehicle and XPro1595-treated rats.
Protein markers included the AMPA receptor subunits GluR1 and
GluR2, and the NMDA receptor subunits NR1, NR2A, and
NR2B (Figure 4A). Nearly all of the glutamate receptor subunits
investigated were insensitive to blockade of TNF/TNFR1
signaling (Figure 4A and 4B). The exception was GluR1, which
showed strikingly higher membrane levels in XPro1595-treated
aged rats (,71% increase, p,0.05).
XPro1595 reduces L-VSCC activity in aged rats
Age-related alterations in short and long-lasting forms of
synaptic plasticity appear to be strongly linked to the activity of
L-VSCCs [37,41], which is increased in CA1 pyramidal neurons
Tumor Necrosis Factor Signaling and Brain Aging
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of L-VSCCs prevents the induction of LTD in aged animals [37],
much like what is seen with TNF blockade (Figure 3D).
Interestingly, TNF has been shown to potentiate L-VSCC activity
in neuronal cultures [11], suggesting that blockade of TNF/
TNFR1 signaling may reduce L-VSCC activity in aged rats. To
test this possibility, an additional cohort of aged rats received
intrahippocampal perfusions of vehicle (n=12) or XPro1595
(0.08 mg/kg/day; n=14) across six weeks, followed by extraction
of hippocampi for preparation of ‘‘zipper slices’’ as described
[13,25]. Cleanly exposed CA1 neurons (Figure 5A) were sealed
with a glass micropipette containing recording solution and the
potent L-VSCC agonist Bay-K 8644 to maximize the probability
of L-VSCC openings. L-VSCC activity was recorded in cell-
attached patch mode from a total of 53 cells (25 vehicle, 28
XPro1595). Maximal L-VSCC activity was elicited by step
depolarizations from 270 to +10 mV, and averaged across 45–
50 sweeps. Maximal peak L-VSCC current densities (pA/mm
2 of
membrane) in two or more patches from the same rat were
averaged to produce a single data point for each rat. Average L-
VSCC current (I) density (pA/mM
2) was then compared across
groups using an unpaired t-test. As shown in Figure 5C,
XPro1595-treated aged rats exhibited a 3-fold decrease in cell-
attached L-VSCC current density (p,0.05), suggesting that TNF/
TNFR1 signaling potentiates, or is permissive for L-VSCC activity
in aged rats.
Previous work suggested that the age-related increase in L-
VSCC activity is attributable to an increase in the expression of L-
VSCC CaV1 pore forming subunits [44,45,46], particularly the
CaV1.3 subunit. To determine if XPro1595 effects on L-VSCC
activity are associated with the reduced expression of CaV1
subunits, we measured relative hippocampal membrane protein
levels of CaV1.2 and CaV1.3 in vehicle and XPro1595-treated
aged rats using Western blot. As shown in Figures 5D and 5E,
neither CaV1 subunit was significantly affected by TNF blockade,
suggesting that the observed differences in L-VSCC activity shown
in Figures 5B and 5C are likely the result of functional alterations,
rather than changes in total channel protein levels. However, these
data cannot rule out the possibility that the cell membrane surface
expression of CaV1 subunits was significantly affected by
XPro1595.
Discussion
TNF is among the key cytokines involved in initiating and
maintaining neuroinflammation. Other neurologic processes,
including synaptic function and plasticity, also appear to be
modulated by TNF. Though elevated in the brain during non-
Figure 3. XPro1595 improves learning and synaptic measures. A, For behavioral assays, XPro1595 (0.08 mg/kg/day) was administered to the
hippocampus over a six week period. Performance (mean 6 SEM) in the spatial version of the Morris Water Maze was measured by path length (cm),
and normalized (%) to block one performance levels for each rat. Each group showed significant improvement by block 6 (p,0.01). However,
XPro1595-, but not vehicle-treated, rats showed significant improvement as early as block 2 and 3, suggesting that TNF-blockade accelerates learning
rates during aging. B, Mean EPSP slope amplitudes (vertical SEM bars) were plotted against mean FV amplitudes (horizontal SEM bars) to generate
CA3-CA1 synaptic strength curves. Each average curve was fit with sigmoidal equations and compared across treatment groups using Z tests. Aged
rats that received intraventricular infusions of XPro1595 over a four week period (0.08 mg/kg/day) exhibited a slight, but significant increase in
maximal EPSP amplitude, relative to the vehicle group (z=2.17). Other curve parameters (i.e. slope and half-maximal FV) were not affected by
XPro1595. C, In a twin pulse paradigm (50 ms interpulse interval), the EPSP slope corresponding to pulse 2 (S2) was expressed as a percentage (mean
6 SEM) of the pulse 1 (S1) EPSP slope to obtain measures of paired-pulse facilitation (PPF). No treatment effect was observed for PPF (p=0.27). D,
Time plot showing normalized mean 6 SEM EPSP slope amplitudes collected before (1) and after (2) the delivery of prolonged 1 Hz stimulation (bar,
900 consecutive pulses). The inset shows representative CA1 EPSP waveforms averaged in the pre- (1) and post-1 Hz (2) periods for vehicle and
XPro1595 groups. Scale bars indicate 0.5 mV vertical by 2 ms horizontal. E, Bar graph shows the amount of LTD, expressed as a percentage of the
pre-1 Hz baseline (mean 6 SEM) in each treatment condition. The results revealed significant LTD in vehicle, but not in XPro1595-treated rats (*
p,0.05, repeated measures ANOVA).
doi:10.1371/journal.pone.0038170.g003
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the specific effects of TNF in intact aged animals. TNF primarily
acts on two distinct receptor subtypes, TNFR1 and TNFR2,
which are linked to common and divergent signaling pathways [1].
TNFR1 contains a classic cytoplasmic cell death domain (CDD)
and is coupled to caspases involved in apoptosis, whereas TNFR2
lacks the CDD and activates PI3-kinase signaling cascades
associated with cell survival. The expressional balance of TNFR
subtypes appears to be critical to the function of multiple organ
systems, including brain. For instance, alterations in the balance of
TNFR expression, in favor of TNFR1, are associated with higher
levels of excitotoxic damage in primary neurons [29].
Here, we showed for the first time that the TNFR1:TNFR2
ratio is increased nearly three-fold in the hippocampus of aged,
relative to young adult rats (Figure 1), suggesting that TNF
increasingly acts through TNFR1-coupled pathways during aging.
We next used the novel anti-TNF biologic, XPro1595, to
essentially isolate the contribution of TNF/TNFR1 interactions
to neurologic function in an intact aged rats. XPro1595 is far more
selective for TNF/TNFR1 signaling because it only disrupts the
biological activity of soluble TNF trimers [16], which, in turn,
show far greater affinity to TNFR1, relative to TNFR2 [17].
Similar to previous results obtained in neurodegenerative disease
models [19], chronic intracranial infusion with XPro1595 strongly
suppressed microglial activation in aged rats (see Figure 2A),
confirming the anti-inflammatory actions of this drug. As discussed
further below, XPro1595 also had a positive impact on multiple
other functional outcome measures in aged rats. The unique
pharmacologic mechanism of XPro1595 suggests that age-related
neurologic dysfunction is strongly related to alterations in TNF/
TNR1 signaling. Nonetheless, based on our data alone, we cannot
entirely rule out the possibility that other potentially detrimental
roles involving TNF/TNFR2 signaling contribute to age-related
neurologic changes, since this pathway was not specifically
modulated in this study.
Effects of XPro1595 on synaptic function and plasticity in
aged rats
Memory deficits in aged mammals are widely believed to result
from alterations in the strength and/or plasticity of hippocampal
synapses [47,48,49]. Though specific observations have varied
across labs, attributable, perhaps, to different methodologies and
experimental models [22,50,51], our group and others have shown
that susceptibility to LTD is increased in area CA1 during aging
[36,39,52,53,54]. In Fischer 344 rats, the extent of LTD in CA1 is
inverselycorrelatedwithperformanceontheMorrisswimtask[35].
Moreover, several manipulations that disrupt LTD induction,
including blockade of NMDARs and L-VSCCs [37,55,56],
activation of estrogen receptors [39,54,57] and inhibition of protein
phosphatase signaling pathways [58] have also been shown to
improve cognitive function in aged rodents [20,44,57,59,60].
The present study suggests that TNF/TNFR1 signaling may
also contribute to cognitive decline during aging through its effects
on LTD mechanisms. Similar to a recent study on delayed
eyeblink conditioning [14], chronic blockade of TNF signaling in
aged rats using XPro1595 accelerated acquisition of a Morris swim
task. Conversely, LTD, which was robust in CA1 of vehicle-
treated aged rats, was nearly absent in the XPro1595 group. Aged
rats treated with XPro1595 also exhibited a small, albeit
significant, increase in the maximal evoked EPSP amplitude,
suggesting that TNF/TNFR1 interactions may also have subtle
effects on basal synaptic transmission parameters. Changes in
synaptic function in XPro1595-treated rats may be attributable, in
part, to a selective increase in membrane GluR1 levels (Figure 4).
GluR1 is a vital mechanism for both short and long-lasting
adjustments in synaptic efficacy. Accordingly, the overall levels,
phosphorylation status, and subcellular localization of GluR1 are
closely regulated [61,62]. While it is possible that TNF/TNFR1
signaling helps to suppress GluR1 at the transcriptional level,
previous work showed that TNF modulates GluR trafficking to the
plasma membrane [63], possibly in a TNFR1-dependent manner
[64]. Clearly, aging and TNF-mediated differences in GluR1
transcriptional regulation and subcellular trafficking will require
further consideration using synapse-specific tissue preparations (i.e.
synaptosomes) and/or more targeted molecular approaches.
Interaction between L-VSCCs and TNF during aging
Cognitive and synaptic alterations in aged animals, as well as
numerous age-related diseases, are commonly linked to the
dysregulation of Ca
2+ [9,48,65,66,67,68,69]. Of the many
mechanisms implicated in Ca
2+ dysregulation, L-VSCCs are
perhaps most consistently associated with changes in physiology
and cognition in models of non-pathological aging. Increased
neuronal L-VSCC activity in the hippocampus of aged rats, as first
reported by Thibault and Landfield [13], underlies elevated Ca
2+-
induced Ca
2+ release [70,71,72], augmented post-spike after-
hyperpolarizations [73], impaired synaptic facilitation [41], and
altered thresholds for induction of long-term potentiation (LTP)
and LTD [37] during aging. Moreover, numerous studies have
reported on the efficacy of L-VSCC antagonists on impaired
cognitive function in aged rats [44,60,74].
There are several parallel observations that point to a strong
interaction between L-VSCCs and TNF in the aging brain. L-
VSCCs and TNF are both upregulated during aging and
modulate key physiologic processes in the same direction,
including LTP [75,76], LTD [77] (also see Figure 3D and 3E),
and behavioral acquisition [78,79] (also see Figure 3A). But, more
Figure 4. Effects of XPro1595 on glutamate receptor protein
levels. A, Representative Western blots are shown for AMPA receptor
(GluR1 and GluR2) and NMDA receptor subtypes (NR1, NR2A, and NR2B)
in hippocampal membrane fractions from aged (22 month) rats treated
for four weeks (intraventricular delivery) with vehicle or XPro1595
(0.08 mg/kg/day). The Na/K-ATPase loading control is shown below. B,
XPro1595 treatment resulted in a selective increase in GluR1 levels (*
p,0.05).
doi:10.1371/journal.pone.0038170.g004
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primary hippocampal neuronal cultures [11]. Based on these
observations, we determined the necessity of TNF signaling in the
regulation of L-VSCC activity in individual CA1 neurons of aged
rats using the hippocampal ‘‘zipper’’ slice preparation and on-cell
patch clamp recording. Consistent with a permissive effect of
TNFR1 on L-VSCC function, we observed a significant reduction
in L-VSCC activity in aged rats treated with XPro1595. The
mechanistic basis for TNFR1 actions on L-VSCCs is unknown,
but does not appear to involve an upregulation of the major L-
VSCC pore-forming subunits (see Figure 5D and 5E), though an
effect of XPro1595 on the subcellular trafficking of L-VSCCs
cannot be ruled out. Previous work has identified the involvement
of several critical signaling intermediaries in L-VSCC regulation
during aging including the cAMP-dependent protein kinase [80],
the protein phosphatase calcineurin [25,81], and FK-506 binding
proteins [82]. Each of these mechanisms is stimulated by and/or
interacts with TNF in multiple cell types [83,84,85,86,87,88],
suggesting that the interaction between TNF and L-VSCCs in
aged brain may be multifaceted.
Cellular target of XPro1595: Neurons vs. Glia
As shown in Figure 2, XPro1595 caused a significant reduction
in protein levels for the microglial marker, Iba-1, in aged rats
(Figure 2). It seems likely that this observation is based on reduced
microglial activation, rather than microglial cell loss or apoptosis,
since TNF and/or TNFR1 tends to promote cell death, while
TNFR1 blockade generally improves cell viability [1,29,89].
Similar to our findings, suppression of microglial activation with
XPro1595 has been reported in primary murine microglial
cultures [18] and also in a rodent model of Parkinson’s disease
[19]. Generally, drugs and/or genetic manipulations that reduce
microglial activation also positively affect neuronal function and/
or cognition in experimental models of aging and disease,
probably by suppressing the release of numerous pro-inflamma-
tory cytokines [90,91,92,93,94]. Like many other cytokine
receptors, TNFRs are expressed on both neurons and glial cells
[95]. Thus, it is unclear at this time whether the beneficial effects
of XPro1595 on synaptic plasticity and cognition in aged rats are
attributable to direct actions on neuronal receptors, or to indirect
effects on microglia-based cytokine release, or both. Regardless,
the results strongly suggest the TNF system plays a critical role in
normal, as well as, pathological aging.
Conclusion
The present study used a multi-disciplinary approach to
investigate interactions among TNF signaling, synaptic function,
and Ca
2+ regulation during normal aging. Neuroinflammation,
cognitive deficits, impaired plasticity, and increased L-VSCC
activity were all ameliorated in aged rats following chronic
treatment with the novel anti-TNF biologic XPro1595. The results
suggest that TNF may drive age-related neurologic dysfunction
through differential interactions with TNFR1 and TNFR2.
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Figure 5. XPro1595 reduces L-VSCC activity in CA1 neurons of
aged rats. A, Left panel, Cartoon illustration of a partially dissociated
hippocampal slice in which CA1 is ‘‘unzipped’’ along stratum pyramidale to
expose CA1 neurons for patch clamp recording. Right panel, Photomicro-
graph showing a glass micropipette tip patched onto a CA1 pyramidal
neuron in an ‘‘unzipped’’ slice. B, Three representative L-VSCC current traces
and the average ensemble current (bottom trace) in cell attached patches
from aged rats treated for six weeks (intrahippocampal delivery) with vehicle
or XPro1595 (0.08 mg/kg/day). Traces were taken from 45–50 consecutive
step depolarizations (150 ms duration) from 270 to +10 mV. C, Mean 6
SEM current (I) densities (pA/mm
2) for each treatment group are shown.
XPro1595 significantly reduced VSCC I density nearly three-fold (* p,0.05).
D–E, Representative Western blots (D)a n dm e a n +SEM protein levels (E)f o r
the major pore-forming L-VSCC subunits (CaV1.2 and CaV1.3) from
hippocampal membrane fractions. The Na/K-ATPase served as loading
control. XPro1595 did not significantly alter either CaV1.2 (p=0.17) or CaV1.3
(p=0.63) levels.
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